By Fineline Cube 
China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc., (NYSE: PFE) for the PD-1/VEGF bispecific antibody, SSGJ-707, has officially come into effect. In addition to the previously announced $1.25 billion upfront payment, 3Sbio will receive an additional $150 million. This additional payment secures Pfizer exclusive rights to develop and commercialize SSGJ-707 in mainland China. 3Sbio is also eligible for subsequent payments and double-digit tiered royalties. Concurrently, Pfizer will subscribe to $100 million worth of 3Sbio’s ordinary shares.
SSGJ-707 Development and Collaboration
SSGJ-707, developed by 3Sbio on its proprietary CLF2 platform, is designed to simultaneously inhibit PD-1 and VEGF targets. Pfizer will initiate global Phase III clinical trials for SSGJ-707 in non-small cell lung cancer (NSCLC) and other tumor types, with the first study commencing patient enrollment in the United States.
Manufacturing and Supply Agreement
3Sbio will serve as the preferred manufacturer of SSGJ-707 in mainland China and one of the manufacturers supplying SSGJ-707 to regions outside of the U.S. and China. This strategic partnership underscores the global potential of SSGJ-707 and the commitment of both companies to advancing innovative oncology therapies.-Fineline Info & Tech